Scientific Advisory Board | Immugen BioPharma

Scientific Advisory Board
Collaborative

Immugen has been fortunate to have assembled such an outstanding group of clinicians and scientists who support our research goals. Their continuing achievements are a testament to the value they bring to our shared mutual interests and will hopefully benefit women's health.

Dr Elizabeth Fenjves, PHD CEO and Founder at i2M & Telehealth Consultant

Dr. Elizabeth Fenjves has a Ph.D. in molecular biology from SUNY at Stony Brook and has done extensive research and education in gene therapy of metabolic disorders.

Irwin Goldstein, M.D. University of California at San Diego, Clinical Professor of Surgery. Alvarado Hospital Clinical Director of Sexual Medicine.

Dr. Goldstein has been involved with sexual dysfunction research since the late 1970's.

Thomas J. Hope, Ph.D. Northwestern University, Molecular Biology

Dr. Hope holds a dual appointment as a Professor in the Feinberg School of Medicine in the Department of Cell and Molecular Biology, and Obstetrics and Gynecology at Northwestern University in Chicago.

IN MEMORIAM John W. Huffman, Ph.D. Clemson University, Professor Emeritus, Organic Chemistry

John W. Huffman, Ph.D., was a scientific advisor to Immugen for the past 9 years but his contributions will be remembered more for the compounds that he made available to the research community as a whole.

Preston Marx, Ph.D. Tulane University, Chairman Public Health and Tropical Medicine

Preston has been a pioneering virologist who has a keen interest in the factors which influence the sexual transmission of SIV/HIV, namely the female reproductive hormones.

Sten Vermund, M.D., Ph.D. Anna M.R. Lauder Professor of Public Health, Yale School of Medicine

Sten has been a steadfast member of the SAB since the year 2000 and had written a letter of support for the R21 grant.

Scientific Advisory Board Collaborative

Scientific Advisory Board
Collaborative